Alphatec (ATEC) to Release Earnings on Tuesday

Alphatec (NASDAQ:ATEC) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Alphatec to post earnings of ($0.33) per share for the quarter. Alphatec has set its FY 2024 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The company had revenue of $138.00 million for the quarter, compared to the consensus estimate of $131.90 million. During the same quarter last year, the business posted ($0.33) EPS. The firm’s revenue for the quarter was up 30.3% compared to the same quarter last year. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Trading Up 3.3 %

NASDAQ:ATEC opened at $13.65 on Friday. The company has a market cap of $1.91 billion, a PE ratio of -8.81 and a beta of 1.48. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54. The company has a 50 day simple moving average of $13.39 and a two-hundred day simple moving average of $13.53. Alphatec has a 12 month low of $8.66 and a 12 month high of $19.14.

Analyst Ratings Changes

Several analysts recently commented on the company. Needham & Company LLC lifted their price objective on Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Alphatec in a research report on Wednesday, March 20th. Wells Fargo & Company initiated coverage on shares of Alphatec in a report on Friday, February 9th. They issued an “overweight” rating and a $26.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Monday, March 4th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.63.

Insider Buying and Selling at Alphatec

In other news, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $16.16, for a total transaction of $40,400.00. Following the sale, the executive vice president now directly owns 637,418 shares in the company, valued at approximately $10,300,674.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO John Todd Koning sold 121,601 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $13.30, for a total transaction of $1,617,293.30. Following the completion of the sale, the chief financial officer now owns 430,856 shares in the company, valued at $5,730,384.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Sponsel sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total value of $40,400.00. Following the completion of the transaction, the executive vice president now directly owns 637,418 shares in the company, valued at $10,300,674.88. The disclosure for this sale can be found here. Insiders have sold 285,069 shares of company stock valued at $3,971,495 over the last 90 days. 29.12% of the stock is currently owned by corporate insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.